New registry to monitor Sotatercept's impact on lung disease patients
NCT ID NCT06751082
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is an observational registry that will follow about 120 adults with pulmonary hypertension who are being treated with the drug sotatercept at the Mayo Clinic. Researchers will track changes in quality of life, exercise ability, heart function, and side effects like bleeding. The goal is to understand how well the drug works in everyday medical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2025
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients for whom sotatercept is being or has been prescribed will be identified through the Mayo Pulmonary Hypertension Clinic.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults age 18 or greater who are being treated with sotatercept in the Mayo Pulmonary hypertension clinic. Exclusion Criteria: * Adults lacking capacity to consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pulmonary hypertension are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A 10-Question survey could give brazilian pulmonary hypertension patients a voice in their care
- Inhaled xenon gas could reveal hidden lung vessel disease without catheter
- Inhaled drug aims to ease dangerous lung blood pressure in scarred lungs
- AI plus ultrasound could catch heart and lung decline before it turns critical
- Could a breath of oxygen during dialysis ease a hidden heart risk?
- Can GLP-1 drugs improve heart function during exercise in Obesity-Related heart failure?